NCT01518166View on ClinicalTrials.gov

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
DiabetesHealthy
Interventions
DRUG

liraglutide

Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

DRUG

placebo

Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively

DRUG

atorvastatin

One single dose of 40 mg. Tablet

DRUG

lisinopril

One single dose of 20 mg. Tablet

DRUG

griseofulvin

One single dose of 500 mg. Tablet

DRUG

digoxin

One single dose of 1 mg. Tablet

Trial Locations (1)

75323

Novo Nordisk Investigational Site, Uppsala

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY